Guideline-Endorsed Answers to Key Questions in Nontuberculous Mycobacterial Lung Disease Management

It took 15 years and several doctors to reach a diagnosis of NTM lung disease, but today I am living without the assistance of medications. 

Anonymous Patient Released: September 30, 2021

One of the most frustrating and misunderstood aspects of NTM disease management is the lack of clear correlation between in vitro activity of the drug and the outcome of in vivo treatment.

David E. Griffith, MD Released: December 1, 2021

Attention to safety concerns for patients receiving treatment for NTM lung disease is paramount. Here are some of the steps I take while following patients as they undergo treatment.

Princy N. Kumar, MD, FIDSA, MACP Released: November 30, 2021

Hear insights from 3 faculty experts as they engage in a lively discussion on guideline updates in the diagnosis, monitoring, and treatment of patients with nontuberculous mycobacterial lung disease.

Keira A. Cohen, MD
Program Director David E. Griffith, MD Princy N. Kumar, MD, FIDSA, MACP Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Pharmacists: 1.0 contact hour (0.1 CEUs) Released: November 19, 2021 Expired: No longer available for credit

Emergence of New Guidelines: NTM Lung Disease in 2021

How can we reduce the time to diagnosis of NTM-LD and linkage to care?

How do you decide to start (or not start) treatment for NTM-LD?

What do you monitor for and how often during NTM-LD treatment?

How do you approach treatment-refractory NTM-LD?

Read expert faculty member summaries of guideline updates in the diagnosis, monitoring, and treatment of patients with nontuberculous mycobacterial lung disease (NTM-LD).

David E. Griffith, MD Princy N. Kumar, MD, FIDSA, MACP Released: November 8, 2021